Lefei Sun is a Managing Director and Head of Healthcare for General Atlantic’s China region. Before joining the firm in 2018, Lefei was the Founding Partner of HuaTai Healthcare Investment Fund. Prior to that, Lefei was lead healthcare analyst from Credit Suisse, founding team member of OrbiMed’s Asia fund, and a management consultant from McKinsey & Company, all in the healthcare sector. He has rich experiences in both private and public healthcare investment market and played an instrumental role in the investment of many healthcare leading companies such as Mindray Medical in Medtech and Asia Medical (Wuhan Asia Heart Hospital) in healthcare services.

Mr.Sun holds an M.A. in neuroscience from The Johns Hopkins University Medical School and a B.S. in mathematics and physics from Tsinghua University.

Yu Miao is the Executive Director of GP Healthcare Captial Co.,Ltd, and he is mainly responsible for equity investment focusing on the healthcare industry. Since joining GP Healthcare Capital in 2015, he has led investment in CF PharmTech, Adagene, MicuRx, Eureka Therapeutics, Sinovision, Transthera, etc. Prior to joining GP Healthcare Capital, he worked at Eli Lilly & Co. and Oriza Seed Fund Management Co., Ltd.

Mr. Miao holds an MS in pharmaceutical science from Northeastern University.

Lynn Yang joined Sequoia Capital as a managing director in May 2015 where she focuses on healthcare investment. Prior to joining Sequoia Capital, Ms. Yang worked at Legend Capital as a member of the healthcare team. She has participated in investments in different sectors of the healthcare industry such as Burning Rock, Cstone (2616.HK), JW Therapeutics, Grail, Hongkong Asia Medical etc. Before starting in venture capital, Ms. Yang worked as a business development manager at Johnson & Johnson and a product manager at GE Healthcare.

Ms. Yang holds an MBA from Duke University and a MS in clinical science from Huazhong Technology University.

Chong Xu, Ph.D., is a Principal at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in the U.S. and in China, such as Innovent Biologics and Semma Therapeutics, among others. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a Ph.D. in cell biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

Daniel Auerbach is the Managing Partner of Eight Roads Capital Advisors (Hong Kong) Limited, the Asia Pacific Private Equity and Venture investing arm of FIL Limited (formerly Fidelity International Ltd), an affiliate of one of the world’s largest, independent, privately held money management firms.

Mr. Auerbach has held this role since 1994, representing a significant component of his 30 years in Asia as an early pioneer and leader in the development of Asia’s Private Equity industry. Through his business involvement Mr. Auerbach is associated with the establishment of some of the region’s most successful independent businesses in the areas of the internet, IT out-sourcing, software, media, telecommunications, education, business-process outsourcing, infrastructure, health care services, bio-chemistry research services, bio-technology and bio-pharma development and distribution. Mr. Auerbach has held key board roles with a multitude of companies, including the Alibaba Group, Wuxi Pharmatech, AsiaInfo, Asia Renal Care and several others. He continues to serve on a number of Boards of Asia’s leading emerging businesses. Mr. Auerbach is a member of Fidelity’s Senior Leadership throughout Asia Pacific.

Prior to 1994 for a period spanning over 7 years, Mr. Auerbach was a Partner at Arral and Partners, one of Asia’s first independent private equity firms, based in Hong Kong. Among other things Arral and Partners was the founding investor in the Aman Resorts Hotel Group, where Mr. Auerbach played a key role in its global development since its establishment in 1987. From 1980-1985 Mr. Auerbach was based in Boston working at Fidelity as an equity analyst and portfolio management assistant to Peter Lynch, the manager of the Fidelity Magellan Fund.

Apart from his business activities, Mr. Auerbach is a member of various international and local businesses, philanthropic and civic organisations. He is a Trustee of Hong Kong‘s World Wildlife Fund; A Trustee of the Hong Kong Plastic Oceans Foundation; A member of the Board of Overseers at the Morningside College, Asia’s first liberal arts college based in Hong Kong; A member of the Presidential Advisory Board of the Berklee College of Music in Boston. Mr. Auerbach also plays a primary role in leading a multitude of initiatives on behalf of the Fidelity Charitable Foundations.

In 2000, Mr. Auerbach was nominated by the World Economic Forum as one of its Young Global Leaders.

Mr. Auerbach holds a B.A from Dartmouth College (1980) in economics and foreign languages and an M.B.A. from The Harvard Business School in Boston. Mr. Auerbach lives in Hong Kong.

Peter (Peizhi) Luo, Ph.D., co-founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate about devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. Dr. Luo has focused on studying the fundamental mechanisms of protein folding and design principle, and particularly by computational and experimental approaches for the last 20 years.

Prior to founding Adagene, Dr. Luo was the co-founder, Chief Technology Officer, President and Director of Abmaxis Inc, which was acquired by Merck & Co. in 2006. Dr. Luo then served as Director of Biologics Technology at Merck. Prior to Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor.

Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. in applied chemistry from Peking University.